Last update 21 Nov 2024
CBP-1008
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Peptide drug conjugates |
Synonyms |
Target |
Mechanism FOLR1 agonists(Folate receptor alpha agonists), TRPV6 antagonists(Transient receptor potential cation channel subfamily V member antagonists), Tubulin inhibitors + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationSpecial Review Project (CN), Fast Track (US) |
Login to view timeline
Structure
Boost your research with our ADC technology data.
login
or
Related
4
Clinical Trials associated with CBP-1008评价注射用CBP-1008在叶酸受体α（FRα）阳性的铂耐药晚期上皮性卵巢癌、原发性腹膜癌和输卵管癌患者中的疗效和安全性的开放标签、多中心Ⅱ期单臂研究
[Translation] An open-label, multicenter, phase II, single-arm study to evaluate the efficacy and safety of CBP-1008 for injection in patients with folate receptor α (FRα)-positive, platinum-resistant advanced epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer
多中心、开放、评价注射用 CBP-1008 周疗方案在 FOLR1 和/或 TRPV6 表达阳性的晚期恶性实体瘤患者中安全性、耐受性和药代动力学特征以及在选定适应症中扩展的 Ia、Ib 期研究
[Translation] A multicenter, open-label, Phase Ia and Ib study to evaluate the safety, tolerability, and pharmacokinetic characteristics of an 8-week treatment regimen of CBP-100 for injection in patients with advanced malignant solid tumors that are positive for FOLR1 and/or TRPV6 expression, and to expand in selected indications
评价注射用CBP-1008在晚期恶性实体瘤患者中安全性、耐受性、药代动力学特征和在选定适应症中扩展的Ia、Ib期研究
[Translation] Phase Ia and Ib studies to evaluate the safety, tolerability, pharmacokinetic characteristics and expansion of CBP-1008 for injection in patients with advanced malignant solid tumors in selected indications
100 Clinical Results associated with CBP-1008
Login to view more data
100 Translational Medicine associated with CBP-1008
Login to view more data
100 Patents (Medical) associated with CBP-1008
Login to view more data
100 Deals associated with CBP-1008
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Phase 3 | CN | - | |
| Ovarian Cancer | Phase 3 | CN | - | |
| Platinum-Resistant Epithelial Ovarian Carcinoma | Phase 2 | CN | 15 Feb 2023 | |
| Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | CN | 15 Feb 2023 | |
| Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | CN | 15 Feb 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 06 Mar 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT04740398 (ASCO2023) Manual  | Phase 1 | 82 | (platinum-resistant ovarian cancer (PROC)) | (ghndqwkeut) = Majority of adverse events were mild to moderate. Grade 3/4 treatment-emerging adverse events (TEAEs) occurred in ≥ 3% subjects were neutropenia (n=85), decreased leukocyte count (n=49), anaemia (n=10), AST elevation (n=7), ALT elevation (n=7). sfkojtrfvr (qvxilubqdl ) View more | Positive | 31 May 2023 | |
(FRα expression ≥25% and ≤3 prior treatment regimens (PROC)) | |||||||
Phase 1 | 106 | cyskgyzcxi(ugfsipqdfc) = not observed dzvdgvailo (qvbyrdyxls ) | Positive | 02 Jun 2022 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free